ArticleBreast cancer research : BCR2025
Dissecting the tumor microenvironment in primary breast angiosarcoma: insights from single-cell RNA sequencing.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-omics integration identifies ribosome biogenesis-active macrophage subpopulation and its key gene GNL2 in driving liver hepatocellular carcinoma progression and mechanisms.Cancer cell international · 2026Article
- Research on the role and mechanism of FAT4 in the development and progression of tumor and non-tumor diseases.Discover oncology · 2026Review
- Macrophage-associated prognostic modeling uncovers immunotherapy response mechanisms and defines HAGHL as a novel oncogenic driver in breast cancer.Frontiers in immunology · 2026Article
- Mapping thirty years of tumour-microenvironment-driven drug resistance in breast cancer: a global bibliometric analysis.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAngiosarcoma, a rare and highly aggressive malignancy originating from vascular endothelial cells, is characterized by its rapid progression, high invasiveness, and poor prognosis. Due to the limited understanding of its tumor microenvironment (TME) and the absence of effective treatments, further research is essential to elucidate its pathogenic mechanisms and improve therapeutic strategies.
objectiveThis study aims to characterize the cellular heterogeneity and unique TME of primary breast angiosarcoma using single-cell RNA sequencing (scRNA-seq), to identify potential therapeutic targets and improve clinical outcomes.
methodsTumor samples were obtained from a patient with bilateral primary breast angiosarcoma and two patients with invasive breast cancer. Single-cell RNA sequencing (scRNA-seq) was conducted to capture the transcriptomic profiles of individual cells within the tumor samples. Following stringent quality control, a total of 31,771 cells were analyzed using comprehensive bioinformatics approaches. Cell populations were identified and classified into distinct cell types, and differential gene expression analysis was performed to explore key signaling pathways. Functional enrichment analysis was used to identify pathways related to tumor progression and immune evasion. Additionally, cell-cell communication networks were mapped to understand interactions within the TME, with a focus on pathways that may serve as therapeutic targets.
resultsThe scRNA-seq analysis revealed significant differences in the distribution of perivascular cells, fibroblasts, T cells, endothelial cells, and myeloid cells in breast angiosarcoma compared to invasive breast cancer. Key pathways enriched in angiosarcoma samples included growth factor binding, platelet-derived growth factor binding, and ribosome biogenesis, with abnormal expression of several ribosomal proteins. Notably, genes such as FAT4, KDR, FN1, and KIT were highly expressed in angiosarcoma endothelial cells, correlating with poor prognosis. Cell communication analysis highlighted the CXCL12-CXCR4 axis as a crucial mediator of the TME in angiosarcoma.
conclusionThis study provides critical insights into the TME of primary breast angiosarcoma, highlighting potential molecular targets and pathways for therapeutic intervention. These findings may inform the development of more effective treatment strategies for this rare and challenging tumor type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.